JMP Securities Reiterates “Market Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX)
JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They ...
ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community
FORT LAUDERDALE, FL / ACCESSWIRE / February 11, 2025 / ZEO ScientifiX, Inc. ('ZEO' or the 'Company') (OTCQB:ZEOX), a clinical-stage biopharmaceutical company fo ...
HDAC Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...
Rising Coffee Culture Fuels Growth: Out-of-Home Coffee Market Set for USD 38.50 Billion Valuation by 2035 | Future Market Insights, Inc.
Out-of-home coffee sector sees strong growth, hitting USD 24.50 Bn in 2025, rising to USD 38.50 Bn by 2035. Driven by chain growth, premium blends, tech-driven retail, eco-focus. Hot, iced, RTD ...
Incyte Co. (NASDAQ:INCY) Shares Bought by Blue Trust Inc.
Blue Trust Inc. grew its position in Incyte Co. (NASDAQ:INCY – Free Report) by 124.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 593 ...
MarketWatch22h
Sarepta Therapeutics Inc.
Dyne Therapeutics Inc. 4.43% $1.38B ...